Zolbetuximab plus CAPOX represents a potential new first-line therapy for patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or mG/GEJ adenocarcinoma. The gene discussed is CLDN18; the disease is gastroesophageal junction adenocarcinoma.